Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Aprepitant (EMEND®) is recommended as an option for use within NHS Wales for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients from the age of 6 months to less than 18 years old. Aprepitant is given as part of combination therapy. |
|||
|
|||
Medicine details |
|||
| Medicine name | aprepitant (EMEND®) | ||
| Formulation | 125 mg powder for oral suspension; 80 mg, 125 mg capsule | ||
| Reference number | 2937 | ||
| Indication | Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients from the age of 6 months to less than 18 years old |
||
| Company | Merck Sharp & Dohme Ltd | ||
| BNF chapter | Central nervous system | ||
| Assessment type | Limited | ||
| Status | Recommended | ||
| Advice number | 1816 | ||
| NMG meeting date | 08/06/2016 | ||
| AWMSG meeting date | 13/07/2016 | ||
| Ratification by Welsh Government | 26/07/2016 | ||
| Date of issue | 27/07/2016 | ||
| Date of last review | 26/07/2019 | ||